Brief: Hofseth Cash And Cash Equivalents Rise By NOK 6.2 Mln In Q4
Feb 9 (Reuters) - Hofseth Biocare ASA HBC.OL :
* GROSS MARGIN IN Q4 IS NEGATIVELY IMPACTED BY AN
EXTRAORDINARY
WRITE-DOWN OF 15 MILLION NOK OF OUR EXCESS CALCIUM INVENTORY
* CASH AND CASH EQUIVALENTS INCREASED BY NOK 6.2M DURING
QUARTER,
LEAVING TOTAL HOLDING AT NOK 23.9M AT END OF YEAR
Source text for Eikon: ID:nGNE18RywL
Further company coverage: HBC.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Hofseth Biocare ASA
See all newsBrief: HBC Publishes Clinical Trial, Calls It Paradigm-Changing
Brief: Hofseth Biocare Says Demand Outlook For 2026 Is Improving Rapidly
Norway's Hofseth Biocare Q4 revenue rises on Human Nutrition demand
Brief: Hofseth BioCare To Cancel Subsequent Offering
Brief: Hofseth Biocare Announces Results Of Subsequent Offering